Philippines - English - FDA (Food And Drug Administration)

baxter pharmaceuticals india private limited; importer: claris lifesciences philippines, inc.; distributor: the cathay drug co., inc. - cefepime (as hydrochloride) - powder for injection (im/iv) - 1g

Ireland - English - HPRA (Health Products Regulatory Authority)

claris lifesciences (uk) limited - bupivacaine hydrochloride - solution for injection - 2.5 mg/ml - amides

Ireland - English - HPRA (Health Products Regulatory Authority)

claris lifesciences (uk) limited - bupivacaine hydrochloride - solution for injection - 5.0 mg/ml - amides

United States - English - NLM (National Library of Medicine)

claris lifesciences, inc. - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd) - ampicillin 250 mg - ampicillin for injection, usp is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: respiratory tract infections caused by s. pneumoniae (formerly d. pneumoniae ). staphylococcus aureus (penicillinase and nonpenicillinase-producing), h. influenzae, and group a beta-hemolytic streptococci. bacterial meningitis caused by e. coli, group b streptococci, and other gram-negative bacteria (listeria monocytogenes, n. meningitidis ). the addition of an aminoglycoside with ampicillin may increase its effectiveness against gram-negative bacteria. septicemia and endocarditis caused by susceptible gram-positive organisms including streptococcus sp., penicillin g-susceptible staphylococci, and enterococci. gram-negative sepsis caused by e. coli, proteus mirabilis and salmonella sp. respond to ampicillin. endocarditis due to enterococcal strains usually respond to intravenous therapy. the addition of an aminoglycoside may enhance the effe

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - dobutamine hydrochloride, quantity: 14.01 mg/ml (equivalent: dobutamine, qty 12.5 mg/ml) - injection, concentrated - excipient ingredients: sodium metabisulfite; hydrochloric acid; sodium hydroxide; water for injections - adults who require short-term treatment of cardiac failure secondary to acute myocardial infarction, or cardiac surgery.???

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - metronidazole 5 mg/ml - solution for infusion - 500 mg/100ml - active: metronidazole 5 mg/ml excipient: citric acid monohydrate dibasic sodium phosphate sodium chloride water for injection - metronidazole-claris intravenous infusion is indicated: · for treatment of anaerobic infections in patients for whom oral administration is not possible. · when immediate anti-anaerobic therapy is required. · when prophylactic cover is required at lower abdominal surgical sites presumed contaminated or potentially contaminated by anaerobic micro-organisms. procedures of this type include appendicectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and surgery performed in the presence of anaerobic septicaemia. note: metronidazole is inactive against aerobic or facultative anaerobic bacteria.

United States - English - NLM (National Library of Medicine)

claris lifesciences, inc. - nafcillin sodium (unii: 49g3001bck) (nafcillin - unii:4cnz27m7rv) - nafcillin 1 g - nafcillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. culture and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see clinical pharmacology - susceptibility tests ). nafcillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. nafcillin should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus , therapy should not be continued with nafcillin for injection, usp. to reduce the development of drug-resistant bacteria and maintain the effectiveness of nafcillin for injection and other antibacterial drugs, nafcillin for injection should be used only to treat or prevent infections that are proven or strongly sus

United States - English - NLM (National Library of Medicine)

claris lifesciences, inc - ondansetron hydrochloride (unii: nmh84ozk2b) (ondansetron - unii:4af302esos) - ondansetron 32 mg in 50 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - moxifloxacin hydrochloride, quantity: 1.74 mg/ml - injection, intravenous infusion - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; sodium chloride - moxifloxacin-baxter is indicated for treatment of adults who require initial i.v. therapy for the treatment of infections in the conditions: ? community acquired pneumonia (caused by susceptible organisms) ? acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics moxifloxacin-baxter is indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents, (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin-baxter may be initiated, in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - flumazenil, quantity: 1 mg - injection, solution - excipient ingredients: disodium edetate; sodium chloride; water for injections; sodium hydroxide; glacial acetic acid - flumazenil-baxter is indicated for use in hospitalised patients for the reversal of acute benzodiazepine effects (overdose or therapeutic). hospitalised patients are patients admitted to hospital, inpatient care and under continued professional observation while under the influence of flumazenil-claris. not to be used in outpatients or short stay patients. not to be used as a diagnostic.